Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
NORTHBROOK, Ill., Nov. 3, 2014 /PRNewswire/ -- Astellas announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of...
SAN FRANCISCO, CA and NORTHBROOK, IL – October 30, 2014 – Medivation Inc. (NASDAQ: MDVN) and Astellas today announced plans to initiate a global Phase 3 clinical trial that will evaluate the...
Company is Exclusive Healthcare Sponsor of USA Eagles vs. New Zealand All Blacks Rugby Match at Soldier Field on Nov. 1 NORTHBROOK, Ill., Oct. 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., in...
NORTHBROOK, Ill., Oct. 8, 2014 /PRNewswire/ -- Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3...
Read more about Astellas Presents New Findings For Isavuconazole In Mucormycosis At IDWeek
NORTHBROOK, Ill., Oct. 2, 2014 /PRNewswire/ -- Astellas, a pharmaceutical company based in Northbrook, Ill., launched a new benefits program today to provide support for its almost 3,000 US-based...
NORTHBROOK, Ill., Oct. 1, 2014 /PRNewswire/ -- Astellas has appointed Brian McLellan as the president of Astellas Pharma Technologies in the Americas region. In this role, Brian will be...
Read more about Brian McLellan Promoted to President of Astellas Pharma Technologies
NORTHBROOK, Ill., Sept. 16, 2014 /PRNewswire/ -- Astellas announced today it has appointed Christy Noland as a new director of Business Communications & Advocacy, Urology in the Americas. Noland...
Read more about Christy Noland to Lead Urology Advocacy and Communications for Astellas
WHAT: More than 400 Astellas employees will descend on Dunning Read Conservation Area in Chicago in celebration of Astellas 5th annual Changing Tomorrow Day. The volunteers will build a...
NORTHBROOK, Ill., Sept. 6, 2014 /PRNewswire/ -- Astellas today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for isavuconazole...
NORTHBROOK, Ill., Sept. 5, 2014 /PRNewswire/ -- Astellas today announces the appointment of Andrew Lewis as head of communications for the company's Global Medical & Development (GMD)...
Read more about Andrew Lewis Joins Astellas to Lead Communications for Global Medical & Development
NORTHBROOK, Ill., Sept. 5, 2014 /PRNewswire/ -- Astellas announces today the data that will be presented on the anti-fungal isavuconazole at the 4th Interscience Conference on Antimicrobial Agents...
Read more about Astellas to Showcase Isavuconazole Data at ICAAC
NORTHBROOK, Ill., Sept. 2, 2014 /PRNewswire/ -- Astellas has appointed James Kellerman as the vice president of intellectual property (IP) in the Americas. Kellerman will report directly to Linda...
NORTHBROOK, Ill., July 31, 2014 /PRNewswire/ -- Astellas has appointed Moyra Knight as the head of corporate and employee communications in the Americas region. Knight will report directly to Jeff...
If isavuconazole is approved for invasive candidiasis, QIDP status provides a five-year extension of market exclusivity. NORTHBROOK, Ill., July 16, 2014 /PRNewswire/ -- Astellas today announced...
NORTHBROOK, Ill., July 9, 2014 /PRNewswire/ -- Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for...
NORTHBROOK, Ill., June 26, 2014 /PRNewswire/ -- Astellas announces the appointment of Marty Golden, J.D. as vice president, Government Affairs, which is effective on July 1, 2014. In this role,...
Read more about Astellas Appoints Marty Golden, J.D., as Vice President, Government Affairs
NORTHBROOK, Ill., June 26, 2014 /PRNewswire/ -- Astellas has named Tatjana Dragovic, J.D., vice president and regional compliance officer for its Americas region. In this role, she will oversee...
- Uhlendorf is leaving his current position as Vice President, Communications and Public Affairs at PhRMA - NORTHBROOK, Ill., June 24, 2014 /PRNewswire/ -- Astellas announces the appointment of...
Read more about Astellas Appoints Karl Uhlendorf as Communications and Advocacy Director
Special Patient-Focused Event Kicks Off Astellas' Fifth Annual Changing Tomorrow Day Initiative KISSIMMEE, Fla., June 11, 2014 /PRNewswire/ -- About 1,400 Astellas Pharma employees will be...
-Study appears in June 1 online edition- NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo:...
NORTHBROOK, Ill., May 14, 2014 /PRNewswire/ -- Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European...
Eight abstracts will highlight enzalutamide studies in prostate and breast cancers NORTHBROOK, Ill. and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of...
NORTHBROOK, Ill., May 2, 2014 /PRNewswire/ -- Astellas announces the promotion of Bernhardt Zeiher, M.D. ("Bernie") to the position of executive vice president, Global Development and the...
Read more about Astellas Announces Promotion and New Appointment
- Bloss to serve on Astellas US Management Committee - NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas US LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced...
Read more about Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas
NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that it has reached an...
Read more about Astellas Pharma US, Inc. reaches agreement with U.S. Department of Justice